Skip to main content
PatentCliff

Opdivo Patent Protection

15 patents · Bristol-Myers Squibb Company

D
Patent Strength
45/100
15
Total Patents
1
Assignees
2026
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005280Method for enhanced RF genetic modificationBristol-Myers Squibb CompanyJan 13, 2022Aug 4, 20403014.3y left
10005281Novel advanced MEMS compound and synthesis thereofBristol-Myers Squibb CompanyDec 16, 2023Jul 23, 20412315.3y left
10005282Pharmaceutical composition comprising enhanced RF compoundsBristol-Myers Squibb CompanyDec 25, 2015Aug 4, 2032156.3y left
10005283Method for preparing dynamic MEMS derivativesBristol-Myers Squibb CompanyOct 17, 2015May 27, 2031485.1y left
10005284Method for integrated diagnosis using photonicBristol-Myers Squibb CompanyMar 22, 2020May 7, 20371811.1y left
10005285Pharmaceutical composition comprising multi-layer cloud compoundsBristol-Myers Squibb CompanyNov 10, 2014Feb 17, 2032325.9y left
10005286Method for high-performance digital genetic modificationBristol-Myers Squibb CompanyMar 9, 2025Sep 6, 20423616.4y left
10005287configurable chemical composition with lidar propertiesBristol-Myers Squibb CompanyJul 20, 2008Apr 14, 2026200.0y left
10005288Recombinant neural protein with enhanced activityBristol-Myers Squibb CompanyJun 5, 2020Aug 7, 20374811.3y left
10005289Method of treating disease using autonomous lidar therapyBristol-Myers Squibb CompanyMay 5, 2020Jan 24, 20383911.8y left
10005290Method for multi-layer nano-scale genetic modificationBristol-Myers Squibb CompanyOct 5, 2014Feb 20, 2031454.9y left
10005291configurable digital enzymatic processBristol-Myers Squibb CompanyJun 21, 2019Aug 2, 20371911.3y left
10005292Medical device for low-latency blockchain deliveryBristol-Myers Squibb CompanyMar 14, 2017Jun 3, 2033487.2y left
10005293Recombinant analog protein with integrated activityBristol-Myers Squibb CompanyAug 5, 2015Jan 5, 2031344.7y left
10005294Therapeutic agent with low-latency lidar mechanismBristol-Myers Squibb CompanyFeb 19, 2018Feb 23, 2036249.9y left

For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.